Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 3/20 | 1.00 |
| ▸ | NSD2 | O96028 | 2/20 | 1.00 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18282645 | 1.00 | RAD52 (1.00) | RAD52NSD2RCE1POLBKMT2A | |
| SCHEMBL16491215 | 0.84 | KMT2A (1.00) | RAD52NSD2RCE1KMT2AMEN1 | |
| SCHEMBL16171086 | 0.80 | NSD2 (0.79) | RAD52NSD2RCE1POLBKMT2A | |
| SCHEMBL5456271 | 0.80 | POLB (0.77) | RAD52NSD2RCE1POLBKMT2A | |
| SCHEMBL5457696 | 0.79 | RAD52 (0.65) | RAD52NSD2RCE1POLBKMT2A | |
| SCHEMBL4075245 | 0.76 | POLB (0.63) | RAD52NSD2RCE1POLBKMT2A | |
| SCHEMBL4256228 | 0.73 | POLB (0.69) | RAD52NSD2RCE1POLBKMT2A | |
| SCHEMBL26568771 | 0.70 | ALDH1A1 (0.79) | RAD52KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL26116157 | 0.70 | KDM4E (0.75) | RAD52KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL26568017 | 0.68 | KDM4E (0.66) | RAD52NSD2RCE1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199636-A1 | Inhibitors of RAD52 Recombination Protein and Methods Using Same | UNIV DREXEL (US) | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199636-A1 | Inhibitors of RAD52 Recombination Protein and Methods Using Same | RAD52, RAD50, MRE11 | RAD52 1/4885NSD2 1340/4885RCE1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.